Trial · NCT05785468
A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
NCT05785468, Unknown, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI). Trials, record NCT05785468. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05785468
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
- NCT number
- NCT05785468
- Status
- Unknown
- Enrollment
- 1 participants, estimated
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Conditions
- Thrombotic Thrombocytopenic Purpura
- Interventions
- Caplacizumab
- First posted
- 2023-03-27
- Last updated
- 2023-03-27
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | description and quantification of clinical response in terms of platelet count recovery in patients with aTTP treated t with caplacizumab | 18 months | The primary objective in this study is the description of clinical response in terms of platelet count recovery in patients with aTTP treated with caplacizumab , in addition to PEX and immunosuppression in the real-world setting. |
| Primary | The primary objective in this study is the quantification of clinical response in terms of platelet count recovery in patients with aTTP treated t with caplacizumab | 18 months | The primary objective in this study is the quantification of clinical response in terms of platelet count recovery in patients with aTTP treated with caplacizumab , in addition to PEX and immunosuppression in the real-world setting. |
| Secondary | evaluation of number of exacerbations,rate of relapse and TTP-related mortality | 18 months | Secondary objectives include: a) Number of exacerbations, defined as recurrent thrombocytopenia within 30 days after the end of therapy; |
| Secondary | evaluation of number of exacerbations,rate of relapse and TTP-related mortality | 18 months | Secondary objectives include: b) Rate of relapse, defined as a TTP event occurring more than 30 days after the end of daily plasma exchange; |
| Secondary | evaluation of number of exacerbations,rate of relapse and TTP-related mortality | 18 months | Secondary objectives include: c) Refractoriness; defined by the lack of a doubling of platelet count after 4 days of treatment and a lactate dehydrogenase level that remained above the upper limit of the normal range |
| Secondary | evaluation of number of exacerbations,rate of relapse and TTP-related mortality | 18 months | Secondary objectives include: d) TTP-related mortality |
| Secondary | evaluation of number of exacerbations,rate of relapse and TTP-related mortality | 18 months | Secondary objectives include: e) Evaluation of adverse events |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05785468
GET https://conductscience.org/api/trials/v1/NCT05785468/registered